Genelux Investor Presentation Deck

Competitive Advantages of Olvi-Vec as an Oncolytic Virus Key Takeaways Olvi-Vec Key Advantages: Broad spectrum of activity Tumor selectivity ● ● ● ● ● ● Strong lytic activity / spread Strong immune activator Engineering capability Multiple routes of delivery Nonhuman pathogen Stable DNA virus Cytoplasmic, no genomic integration GENELUX Key Players and Assets GENELUX Olvi-Vec AMGEN Herpes Replimune Herpes Herpes CG ONCOLOGY Daiichi-Sankyo Adenovirus NCOLYTICS Reovirus BIOTECH INC Oncolytic Virus Space Olvi-Vec Key Advantages Target & Treat Metastatic Disease Systemic Delivery and redosing Robust Immune Activation Profile Target & Treat Tumors of Various Size IV dosing is the physician preferred administration technique, and our IV data has the potential to enable physician preferred administration vs. local-delivery-only assets 9

View entire presentation